Comparable stake leader
PERCEPTIVE ADVISORS LLC
SEC ownership of Solid Biosciences Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001707502.
Disclosed value leader
PERCEPTIVE ADVISORS LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- SLDB on Nasdaq
- Parsed ownership sources
- 13F, 13D/G, and 3/4/5
- Largest SEC-reported holder
- PERCEPTIVE ADVISORS LLC
- Latest 13D/G holder
- PERCEPTIVE ADVISORS LLC
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001707502
- Issuer location
- Charlestown, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Solid Biosciences Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PERCEPTIVE ADVISORS LLC
Disclosed value leader
PERCEPTIVE ADVISORS LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13F
13D/G
3/4/5
Lead comparable stake: 13%
13D/G row: PERCEPTIVE ADVISORS LLC
Showing 1-8 of 50 holder rows.
Quick read
PERCEPTIVE ADVISORS LLC leads the comparable SEC ownership view at 13%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PERCEPTIVE ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
PERCEPTIVE ADVISORS LLC
13%
Invus Global Management, LLC
10%
RA CAPITAL MANAGEMENT, L.P.
9.9%
Vestal Point Capital, LP
7.5%
BlackRock, Inc.
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
3/4/5
Company · Director, 10%+ Owner
|
13%
from 13D/G
|
$85,727,851
11,906,646 shares
|
— | 31 Mar 2026 |
| Invus Global Management, LLC |
13D/G
Raymond Debbane
|
10%
|
—
10,066,682 shares
|
$0 | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
9.9%
from 13D/G
|
$67,247,842
9,339,978 shares
|
— | 31 Mar 2026 |
| Vestal Point Capital, LP |
13F
13D/G
Company
|
7.5%
from 13D/G
|
$36,000,000
5,000,000 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
4.7%
from 13D/G
|
$35,700,150
4,958,354 shares
|
— | 31 Mar 2026 |
| Adage Capital Management, L.P. |
3/4/5
13D/G
10%+ Owner
|
1.8%
from 13D/G
|
$32,115,515
4,248,084 shares
|
— | 18 Feb 2025 |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
Company · 10%+ Owner
|
11%
|
$70,623,497
9,808,819 shares
|
— | 31 Mar 2026 |
| Siren, L.L.C. |
13F
Individual
|
8.3%
|
$55,370,916
7,690,405 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$2,681,597.
Buys
$0
Insiders: 0
Sells
$2,681,597
Insiders: 7
Net
-$2,681,597
Shares: -427,620
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 427,620
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 398,523 | $0 | $2,533,696 | -$2,533,696 |
| 6-9 | 0 | 29,097 | $0 | $147,901 | -$147,901 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 26 reporting-owner rows connected to Solid Biosciences Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
26
Largest Forms 3/4/5 holder
Bain Capital Life Sciences Investors, LLC
Net 12M change
-$2,681,597
Latest report
02 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 10%+ Owner | $46,252,926 | Filing P/S | 19 Feb 2025 | ||
| Adage Capital Management, L.P. | 10%+ Owner | $32,115,515 | Filing P/S | 18 Feb 2025 | ||
| Adam Koppel | Director, 10%+ Owner | $22,311,238 | Mixed | 11 Jan 2024 | ||
| RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | $14,996,280 | Filing P/S | 19 Feb 2025 | ||
| BCLS II Equity Opportunities GP, LLC | Director, 10%+ Owner | $5,000,005 | Mixed | 11 Jan 2024 | ||
| Alexander Cumbo | President and CEO, Director | $1,727,605 | -$983,857 | -36% | Mixed | 13 Feb 2026 |
| Joel Solomon Zev Schneider | Chief Operating Officer | $1,306,573 | Mixed | 14 Mar 2022 | ||
| Ilan Ganot | Director | $884,781 | -$82,374 | -8.5% | Mixed | 13 Feb 2026 |
| Ian F. Smith | Director | $832,936 | Mixed | 02 Apr 2026 | ||
| David Tyronne Howton | Chief Operating Officer | $786,383 | -$433,538 | -36% | Mixed | 13 Feb 2026 |
| Kevin Tan | CFO & Treasurer | $705,189 | -$329,507 | -32% | Mixed | 13 Feb 2026 |
| Gabriel Brooks | Chief Medical Officer | $650,926 | -$280,915 | -30% | Mixed | 13 Feb 2026 |
| Jessie Hanrahan | Chief Regulatory Officer | $529,301 | -$297,329 | -36% | Mixed | 13 Feb 2026 |
| Paul Herzich | Chief Technology Officer | $508,381 | -$274,077 | -35% | Mixed | 13 Feb 2026 |
| Jennifer Marlowe | Cso | $398,249 | Mixed | 13 Feb 2024 | ||
| Carl Ashley Morris | Chief Scientific Officer | $128,883 | Mixed | 27 Jan 2023 | ||
| Clare Kahn | Director | $15,794 | Filing P/S | 12 Jun 2025 | ||
| Adam Leo Stone | Director | Mixed | 12 Jun 2025 | |||
| Georgia Keresty | Director | Mixed | 12 Jun 2025 | |||
| Sukumar Nagendran | Director | Mixed | 12 Jun 2025 |
Recent insider transactions for Solid Biosciences Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Ian F. Smith | SLDB | Common Stock | Options Exercise | 2.62% | 3,441 | 134,705 | 02 Apr 2026 | Direct | ||
| Ian F. Smith | SLDB | Restricted Stock Units | Options Exercise | -25% | -3,441 | 10,320 | 02 Apr 2026 | Direct | ||
| Perceptive Advisors Llc | SLDB | Pre-Funded Warrant (right to buy) | Award | 8,912,655 | 8,912,655 | 09 Mar 2026 | See footnote | |||
| Alexander Cumbo | SLDB | Common Stock | Sale | -6.6% | $96,923 | $5.82 | -16,644 | 235,405 | 18 Feb 2026 | Direct |
| Jessie Hanrahan | SLDB | Common Stock | Sale | -5.27% | $24,074 | $5.82 | -4,134 | 74,318 | 18 Feb 2026 | Direct |
| Ilan Ganot | SLDB | Common Stock | Sale | -8.82% | $15,478 | $5.82 | -2,658 | 27,474 | 18 Feb 2026 | Wife |
| Paul Herzich | SLDB | Common Stock | Sale | -4.74% | $21,057 | $5.82 | -3,616 | 72,638 | 18 Feb 2026 | Direct |
| David Tyronne Howton | SLDB | Common Stock | Sale | -6.64% | $43,494 | $5.82 | -7,469 | 105,077 | 18 Feb 2026 | Direct |
| Gabriel Brooks | SLDB | Common Stock | Sale | $0 | 0 | 89,466 | 18 Feb 2026 | Direct | ||
| Kevin Tan | SLDB | Common Stock | Sale | -5.16% | $31,469 | $5.82 | -5,404 | 99,422 | 18 Feb 2026 | Direct |
| Alexander Cumbo | SLDB | Common Stock | Options Exercise | 13.5% | 30,031 | 252,049 | 13 Feb 2026 | Direct | ||
| Alexander Cumbo | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -30,031 | 60,063 | 13 Feb 2026 | Direct | ||
| Jessie Hanrahan | SLDB | Common Stock | Options Exercise | 11.6% | 8,125 | 78,452 | 13 Feb 2026 | Direct | ||
| Jessie Hanrahan | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -8,125 | 16,250 | 13 Feb 2026 | Direct | ||
| Ilan Ganot | SLDB | Common Stock | Options Exercise | 19.2% | 4,861 | 30,132 | 13 Feb 2026 | Wife | ||
| Ilan Ganot | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -4,861 | 9,722 | 13 Feb 2026 | Wife | ||
| Paul Herzich | SLDB | Common Stock | Options Exercise | 10.4% | 7,187 | 76,254 | 13 Feb 2026 | Direct | ||
| Paul Herzich | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -7,187 | 14,376 | 13 Feb 2026 | Direct | ||
| David Tyronne Howton | SLDB | Common Stock | Options Exercise | 15% | 14,687 | 112,546 | 13 Feb 2026 | Direct | ||
| David Tyronne Howton | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -14,687 | 29,376 | 13 Feb 2026 | Direct | ||
| Gabriel Brooks | SLDB | Common Stock | Options Exercise | 13% | 10,937 | 95,029 | 13 Feb 2026 | Direct | ||
| Gabriel Brooks | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -10,937 | 21,876 | 13 Feb 2026 | Direct | ||
| Kevin Tan | SLDB | Common Stock | Options Exercise | 11.3% | 10,625 | 104,826 | 13 Feb 2026 | Direct | ||
| Kevin Tan | SLDB | Restricted Stock Units | Options Exercise | -33.3% | -10,625 | 21,250 | 13 Feb 2026 | Direct | ||
| David Tyronne Howton | SLDB | Common Stock | Sale | -16.2% | $121,713 | $6.44 | -18,894 | 97,859 | 04 Feb 2026 | Direct |
| Alexander Cumbo | SLDB | Common Stock | Sale | -18% | $315,093 | $6.44 | -48,913 | 222,018 | 04 Feb 2026 | Direct |
| Ilan Ganot | SLDB | Common Stock | Sale | -22.2% | $46,414 | $6.44 | -7,205 | 25,271 | 04 Feb 2026 | Wife |
| Kevin Tan | SLDB | Common Stock | Sale | -13.6% | $95,231 | $6.44 | -14,783 | 94,201 | 04 Feb 2026 | Direct |
| Gabriel Brooks | SLDB | Common Stock | Sale | -13% | $81,271 | $6.44 | -12,616 | 84,092 | 04 Feb 2026 | Direct |
| Jessie Hanrahan | SLDB | Common Stock | Sale | -14.9% | $79,545 | $6.44 | -12,348 | 70,327 | 04 Feb 2026 | Direct |
| Paul Herzich | SLDB | Common Stock | Sale | -13.6% | $70,249 | $6.44 | -10,905 | 69,067 | 04 Feb 2026 | Direct |
| Kevin Tan | SLDB | Common Stock | Sale | -19.8% | $172,747 | $6.44 | -26,837 | 108,984 | 02 Feb 2026 | Direct |
| Jessie Hanrahan | SLDB | Common Stock | Sale | -24.3% | $170,803 | $6.44 | -26,535 | 82,675 | 02 Feb 2026 | Direct |
| Gabriel Brooks | SLDB | Common Stock | Sale | -22.7% | $182,390 | $6.44 | -28,335 | 96,708 | 02 Feb 2026 | Direct |
| Paul Herzich | SLDB | Common Stock | Sale | -24.7% | $168,969 | $6.44 | -26,250 | 79,972 | 02 Feb 2026 | Direct |
| Alexander Cumbo | SLDB | Common Stock | Sale | -22.8% | $516,613 | $6.44 | -80,258 | 270,931 | 02 Feb 2026 | Direct |
| David Tyronne Howton | SLDB | Common Stock | Sale | -24.4% | $243,128 | $6.44 | -37,771 | 116,753 | 02 Feb 2026 | Direct |
| Kevin Tan | SLDB | Common Stock | Options Exercise | 32.2% | 33,075 | 135,821 | 31 Jan 2026 | Direct | ||
| Kevin Tan | SLDB | Restricted Stock Units | Options Exercise | -25% | -33,075 | 99,225 | 31 Jan 2026 | Direct | ||
| Jessie Hanrahan | SLDB | Common Stock | Options Exercise | 33.9% | 27,625 | 109,210 | 31 Jan 2026 | Direct | ||
| Jessie Hanrahan | SLDB | Restricted Stock Units | Options Exercise | -25% | -27,625 | 82,875 | 31 Jan 2026 | Direct | ||
| Gabriel Brooks | SLDB | Common Stock | Options Exercise | 29.2% | 28,225 | 125,043 | 31 Jan 2026 | Direct | ||
| Gabriel Brooks | SLDB | Restricted Stock Units | Options Exercise | -25% | -28,225 | 84,675 | 31 Jan 2026 | Direct | ||
| Paul Herzich | SLDB | Common Stock | Options Exercise | 30.3% | 24,675 | 106,222 | 31 Jan 2026 | Direct | ||
| Paul Herzich | SLDB | Restricted Stock Units | Options Exercise | -25% | -24,675 | 74,025 | 31 Jan 2026 | Direct | ||
| Ilan Ganot | SLDB | Common Stock | Options Exercise | 85.8% | 15,000 | 32,476 | 31 Jan 2026 | Wife | ||
| Ilan Ganot | SLDB | Restricted Stock Units | Options Exercise | -25% | -15,000 | 45,000 | 31 Jan 2026 | Wife | ||
| Alexander Cumbo | SLDB | Common Stock | Options Exercise | 40% | 100,400 | 351,189 | 31 Jan 2026 | Direct | ||
| Alexander Cumbo | SLDB | Restricted Stock Units | Options Exercise | -25% | -100,400 | 301,200 | 31 Jan 2026 | Direct | ||
| David Tyronne Howton | SLDB | Common Stock | Options Exercise | 37.8% | 42,275 | 154,254 | 31 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.